New combo attack on breast cancer brain tumors shows promise in early trial
NCT ID NCT07539753
First seen Apr 23, 2026 · Last updated May 05, 2026 · Updated 2 times
Summary
This study is for people with a common type of breast cancer (HR+/HER2-) that has spread to the brain. It combines brain radiation with two drugs: dalpiciclib (a targeted therapy) and hormone therapy. The goal is to see if this triple approach can better control the brain tumors and delay their growth. About 46 participants will receive the treatment and be followed for at least 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.